Zacks Research Raises Earnings Estimates for Kodiak Sciences

Kodiak Sciences Inc. (NASDAQ:KOD - Free Report) - Equities researchers at Zacks Research increased their Q3 2025 earnings per share estimates for shares of Kodiak Sciences in a report released on Tuesday, October 22nd. Zacks Research analyst R. Department now expects that the company will earn ($1.10) per share for the quarter, up from their previous forecast of ($1.13). The consensus estimate for Kodiak Sciences' current full-year earnings is ($3.52) per share. Zacks Research also issued estimates for Kodiak Sciences' Q4 2025 earnings at ($1.17) EPS, FY2025 earnings at ($4.00) EPS, Q1 2026 earnings at ($0.93) EPS, Q2 2026 earnings at ($0.85) EPS, Q3 2026 earnings at ($1.04) EPS and FY2026 earnings at ($3.82) EPS.

Separately, HC Wainwright reaffirmed a "neutral" rating and issued a $3.00 target price on shares of Kodiak Sciences in a research note on Tuesday, September 24th. Two analysts have rated the stock with a sell rating, two have given a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $5.00.

Kodiak Sciences Stock Up 9.0 %

NASDAQ KOD traded up $0.31 during trading hours on Friday, hitting $3.74. 424,482 shares of the company's stock traded hands, compared to its average volume of 482,793. Kodiak Sciences has a 52-week low of $1.37 and a 52-week high of $7.77. The firm's 50-day moving average is $2.73 and its 200-day moving average is $2.96.

Kodiak Sciences (NASDAQ:KOD - Get Free Report) last released its earnings results on Wednesday, August 14th. The company reported ($0.86) earnings per share for the quarter, beating the consensus estimate of ($0.87) by $0.01.

Hedge Funds Weigh In On Kodiak Sciences

Institutional investors have recently modified their holdings of the business. American Century Companies Inc. increased its stake in shares of Kodiak Sciences by 18.5% during the second quarter. American Century Companies Inc. now owns 54,323 shares of the company's stock worth $128,000 after buying an additional 8,470 shares during the period. Headlands Technologies LLC purchased a new stake in shares of Kodiak Sciences in the 1st quarter valued at approximately $50,000. Vanguard Group Inc. raised its holdings in shares of Kodiak Sciences by 0.7% in the 1st quarter. Vanguard Group Inc. now owns 1,654,448 shares of the company's stock valued at $8,702,000 after purchasing an additional 10,978 shares in the last quarter. Nan Fung Group Holdings Ltd raised its holdings in shares of Kodiak Sciences by 62.7% in the 1st quarter. Nan Fung Group Holdings Ltd now owns 31,922 shares of the company's stock valued at $168,000 after purchasing an additional 12,300 shares in the last quarter. Finally, SG Americas Securities LLC purchased a new stake in shares of Kodiak Sciences during the 3rd quarter worth $33,000. Institutional investors and hedge funds own 89.06% of the company's stock.

Kodiak Sciences Company Profile

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.